K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · PFE
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | PFE | PFIZER INC. | MILLER STRATEGIES, LLC | $150K | Medicare and healthcare policy issues as they relate to drug pricing. Oppose IRA, PREP Act and vaccine liability. General issues with tax reform and foreign tax issues. Issues related to drug consolidation. |
| 2026-04-20 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Drug pricing and prescription digital therapeutics |
| 2026-04-20 | PFE | PFIZER INC | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
| 2026-04-20 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21. Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Policies impacting post pandemic public health emerge |
| 2026-04-20 | PFE | PFIZER INC. | THE DUBERSTEIN GROUP INC. | $60K | Issues related to FY27 health appropriations Issues related to 340B Program Issues related to drug pricing |
| 2026-04-20 | PFE | PFIZER | RESOLUTION PUBLIC AFFAIRS, LLC | $60K | Issues related to drug development and pricing, generally vaccine safety and access, generally the 340B program, Issues related to pharmacy benefit managers, generally. H.R. 5509, the Safe Step Act Direct-to-Patient Prescription Drug Purchase Platforms Most Favored Nation drug pricing 340B HHS Pilot Program Model |
| 2026-04-20 | PFE | PFIZER INC. | TODD STRATEGY GROUP | $60K | Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. Issues related to tariff and trade policy. International Supply Chain. Issues related to tariff and trade policy. |
| 2026-04-20 | PFE | PFIZER INC | AKIN GUMP STRAUSS HAUER & FELD | $50K | |
| 2026-04-17 | PFE | PFIZER INC. | PFIZER INC. | $4.4M | Intellectual Property Protections Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues International Supply Chain Market Access Most Fa |
| 2026-04-17 | PFE | PFIZER INC. | MARSHALL & POPP, LLC | $60K | Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patie |
| 2026-04-13 | PFE | PFIZER INC | ALTRIUS GROUP, LLC | $0 | |
| 2026-04-02 | PFE | PFIZER INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $110K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 163(j), and 174. |
| 2026-03-17 | PFE | PFIZER INC. | TODD STRATEGY GROUP | $60K | Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025. Issues related to tariff and trade policy. International Supply Chain. Issues related to tariff and trade policy. |
| 2026-03-17 | PFE | PFIZER INC. | TODD STRATEGY GROUP | $60K | Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. Issues related to tariff and trade policy. International Supply Chain. Issues related to tariff and trade policy. |
| 2026-03-17 | PFE | PFIZER INC. | TODD STRATEGY GROUP | $20K | Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025. Issues related to tariff and trade policy. International Supply Chain. Issues related to tariff and trade policy. |
| 2026-03-17 | PFE | PFIZER INC. | TODD STRATEGY GROUP | $0 | Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy. International Supply Chain. Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy. International Supply Chain. Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy. International Supply Chain. |
| 2026-03-12 | PFE | PFIZER INC. | PFIZER INC. | $2.9M | Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA) |
| 2026-03-12 | PFE | PFIZER INC. | PFIZER INC. | $1.8M | Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inf |
| 2026-01-23 | PFE | PFIZER INC. | PFIZER INC. | $2.8M | Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA) |
| 2026-01-20 | PFE | PFIZER INC. | PFIZER INC. | $1.7M | Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inf |
| 2026-01-20 | PFE | PFIZER INC. | MILLER STRATEGIES, LLC | $120K | Medicare and healthcare policy issues as they relate to drug pricing. Oppose IRA, PREP Act and vaccine liability. General issues with tax reform and foreign tax issues. Issues related to drug consolidation. |
| 2026-01-20 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Drug pricing and prescription digital therapeutics |
| 2026-01-20 | PFE | PFIZER INC | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
| 2026-01-20 | PFE | PFIZER | RESOLUTION PUBLIC AFFAIRS, LLC | $60K | Issues related to drug development and pricing, generally vaccine safety and access, generally the 340B program, Issues related to pharmacy benefit managers, generally. |
| 2026-01-20 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21. Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Policies impacting post pandemic public health emerge |
| 2026-01-20 | PFE | PFIZER INC. | THE DUBERSTEIN GROUP INC. | $60K | |
| 2026-01-20 | PFE | PFIZER INC | AKIN GUMP STRAUSS HAUER & FELD | $50K | |
| 2026-01-20 | PFE | PFIZER INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 164(a), 951A, 250, 163(j), and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70303, 70302). |
| 2026-01-16 | PFE | PFIZER INC. | MARSHALL & POPP, LLC | $60K | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. |
| 2026-01-12 | PFE | PFIZER INC | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
| 2026-01-12 | PFE | PFIZER INC | ALTRIUS GROUP, LLC | $30K | Medical Supply Chain Resiliency Act; USMCA enforcement; Promotion of robust IP protection for biopharma innovations before WTO and in current and future FTAs |
| 2026-01-12 | PFE | PFIZER INC | BGR GOVERNMENT AFFAIRS | $0 | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
| 2025-10-20 | PFE | PFIZER INC. | PFIZER INC. | $3.7M | HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of |
| 2025-10-20 | PFE | PFIZER INC. | PFIZER INC. | $2.7M | Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA) |
| 2025-10-20 | PFE | PFIZER INC. | MILLER STRATEGIES, LLC | $120K | General issues with tax reform and foreign tax issues. Medicare and healthcare policy issues as they relate to drug pricing. Oppose IRA, PREP Act and vaccine liability. |
| 2025-10-20 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Implementation of the drug pricing provisions in the Inflation Reduction Act Drug pricing and prescription digital therapeutics |
| 2025-10-20 | PFE | PFIZER INC | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
| 2025-10-20 | PFE | PFIZER INC. | MARSHALL & POPP, LLC | $60K | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. |
| 2025-10-20 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health. Issues related to pharmaceutical manufacturing and development. General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. P |
| 2025-10-20 | PFE | PFIZER INC. | THE DUBERSTEIN GROUP INC. | $60K | Issues related to the 340B program Safe Step Act |
| 2025-10-20 | PFE | PFIZER INC | AKIN GUMP STRAUSS HAUER & FELD | $50K | |
| 2025-10-20 | PFE | PFIZER | RESOLUTION PUBLIC AFFAIRS, LLC | $40K | Issues related to drug development and pricing, generally vaccine safety and access, generally the 340B program, Issues related to pharmacy benefit managers, generally. |
| 2025-10-16 | PFE | PFIZER INC | ALTRIUS GROUP, LLC | $30K | Medical Supply Chain Resiliency Act; Promotion of robust IP protection for biopharma innovations before WTO and in current and future FTAs |
| 2025-10-16 | PFE | PFIZER | RESOLUTION PUBLIC AFFAIRS, LLC | $0 | Issues impacting Rx development and sales, generally |
| 2025-10-14 | PFE | PFIZER INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 164(a), 951A, 250, 163(j), and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70303, 70302). |
| 2025-08-18 | PFE | PFIZER INC. | PFIZER INC. | $3.7M | HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of |
| 2025-08-07 | PFE | PFIZER INC | ALTRIUS GROUP, LLC | $30K | Medical Supply Chain Resiliency Act; Promotion of robust IP protection for biopharma innovations before WTO and in current and future FTAs |
| 2025-07-21 | PFE | PFIZER INC. | PFIZER INC. | $3.5M | HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of |
| 2025-07-21 | PFE | PFIZER INC. | MILLER STRATEGIES, LLC | $120K | Medicare and healthcare policy issues as they relate to drug pricing. Oppose IRA, PREP Act and vaccine liability. General issues with tax reform and foreign tax issues. |
| 2025-07-21 | PFE | PFIZER INC. | MARSHALL & POPP, LLC | $60K | Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 1, FY25 budget reconciliation. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation F |
| 2025-07-21 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Implementation of the drug pricing provisions in the Inflation Reduction Act Drug pricing and prescription digital therapeutics |
| 2025-07-21 | PFE | PFIZER INC | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
| 2025-07-21 | PFE | PFIZER INC. | THE DUBERSTEIN GROUP INC. | $60K | PBM issues Issues related to the 340B program Issues related to federal health programming |
| 2025-07-21 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN. Tax issues affecting the pharmaceutical industry including international tax; including tax issues under consideration for reconciliation legislation and H.R. 1, One Big Beautiful Bill Act". Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actio |
| 2025-07-21 | PFE | PFIZER INC | AKIN GUMP STRAUSS HAUER & FELD | $50K | Issues related to trade and tariffs. |
| 2025-07-18 | PFE | PFIZER INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 164(a), 951A, 250, 163(j), and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70303, 70302). |
| 2025-07-15 | PFE | PFIZER INC | ALTRIUS GROUP, LLC | $30K | Medical Supply Chain Resiliency Act; Promotion of robust IP protection for biopharma innovations before WTO and in current and future FTAs |
| 2025-04-21 | PFE | PFIZER INC. | PFIZER INC. | $4.2M | H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 Budget Reconciliation S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act |
| 2025-04-21 | PFE | PFIZER INC. | MILLER STRATEGIES, LLC | $120K | Medicare and healthcare policy issues as they relate to drug pricing. Oppose IRA, PREP Act and vaccine liability. General issues with tax reform and foreign tax issues. |
| 2025-04-21 | PFE | PFIZER INC. | MARSHALL & POPP, LLC | $60K | Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7. Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. |
| 2025-04-21 | PFE | PFIZER INC | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
| 2025-04-21 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Pharmacy benefit manager reform proposals. Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. Issues related to pharmaceutical manufacturing and development, trade and tariffs. Legislative proposals related to WTO TRIPS Waiver. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunizatio |
| 2025-04-21 | PFE | PFIZER INC. | THE DUBERSTEIN GROUP INC. | $60K | PBM issues Issues related to the 340B program |
| 2025-04-21 | PFE | PFIZER INC | AKIN GUMP STRAUSS HAUER & FELD | $50K | |
| 2025-04-21 | PFE | PFIZER INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 164(a), 951A, 250, 163(j), 174 and 41 (H.R. 1990, H.R. 574, S. 187, H.R. 1062). |
| 2025-04-21 | PFE | PFIZER INC. | AVOQ, LLC | $20K | General health issues |
| 2025-04-21 | PFE | PFIZER | SHOOK, HARDY & BACON, LLP | $0 | |
| 2025-04-18 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Implementation of the drug pricing provisions in the Inflation Reduction Act Drug pricing and prescription digital therapeutics |
| 2025-04-16 | PFE | PFIZER INC | ALTRIUS GROUP, LLC | $20K | Medical Supply Chain Resiliency Act; Promotion of robust IP protection for biopharma innovations before WTO and in current and future FTAs |
| 2025-03-21 | PFE | PFIZER INC. | PFIZER INC. | $3.7M | March-in Framework Guidance and Policies IP Issues Digital Patent Thickets and Product Hopping Pandemic Preparedness/PAHPA Drug Pricing/Inflation Reduction Act: HR7174; Medicare Price Setting PBM Transparency and Reform: S1375/HH830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR5378 - Lower Costs More Transparency Act Inflation Reduction Act /Medicare Price Setting 340B Reform Cell and Gene Therapy Access Model HR1458 - Access to Prescription Digital Therapeutics Act of 2023 VICP Reform and Excise Tax International Supply Chain Global Access to Medicines Pandemic Preparedness |
| 2025-03-21 | PFE | PFIZER INC. | PFIZER INC. | $1.6M | Appropriations Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act S 723/HR 1458 - Access to Prescription Digital Therapeutics Act HR 8816 - Ame |
| 2025-03-20 | PFE | PFIZER INC. | PFIZER INC. | $2.4M | Appropriations Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act S 723/HR 1458 - Access to Prescription Digital Therapeutics Act HR 8816 - Ame |
| 2025-02-14 | PFE | PFIZER INC. | PFIZER INC. | $2.8M | Appropriations Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act S 723/HR 1458 - Access to Prescription Digital Therapeutics Act HR 8816 - Ame |
| 2025-01-22 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158). Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. |
| 2025-01-21 | PFE | PFIZER INC. | PFIZER INC. | $2.8M | Appropriations Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act S 723/HR 1458 - Access to Prescription Digital Therapeutics Act HR 8816 - Ame |
| 2025-01-21 | PFE | PFIZER INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $70K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 163(j), 174 and 41. (H.R. 2673, H.R. 7024). |
| 2025-01-21 | PFE | PFIZER INC. | MARSHALL & POPP, LLC | $60K | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. H.R.10545, FY25 Continuing Appropriations. Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Pati |
| 2025-01-21 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Implementation of the drug pricing provisions in the Inflation Reduction Act Access to Prescription Digital Therapeutics Act (H.R. 1458) H.R. 8816, the American Medical Innovation and Investment Act |
| 2025-01-21 | PFE | PFIZER INC. | THE DUBERSTEIN GROUP INC. | $60K | Issues related to the 340B program Issues related to the Vaccine Injury Compensation Program excise tax PBM issues Issues related to drug pricing |
| 2025-01-21 | PFE | PFIZER INC | AKIN GUMP STRAUSS HAUER & FELD | $50K | |
| 2025-01-21 | PFE | PFIZER INC. | AVOQ, LLC | $50K | Issues related to the Vaccine Injury Compensation Program General health issues, including H.R. 5539/S. 3131, Optimizing Research Progress Hope And New Cures (ORPHAN Cures) Act Issues related to a Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver for COVID-19 therapeutics |
| 2025-01-21 | PFE | PFIZER INC. | MILLER STRATEGIES, LLC | $40K | Medicare and healthcare policy issues as they relate to drug pricing. Oppose IRA, PREP Act and vaccine liability. General issues with tax reform and foreign tax issues. |
| 2025-01-21 | PFE | PFIZER | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $30K | Support increased funding for the CDC National Immunization Program (Sec 317 program). Support increased funding for the CDC National Immunization Program (Sec 317 program) |
| 2025-01-21 | PFE | PFIZER | SHOOK, HARDY & BACON, LLP | $0 | |
| 2025-01-20 | PFE | PFIZER INC | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically. |
| 2025-01-20 | PFE | PFIZER INC. | NVG, LLC | $60K | Intellectual property, data exclusivity, and patent eligibility. 340B legislation. Issues related to vaccine injury compensation funds. S.2115/H.R.4307 - Medical Supply Chain Resiliency Act. |
| 2025-01-20 | PFE | PFIZER INC | ALTRIUS GROUP, LLC | $30K | Medical Supply Chain Resiliency Act; Promotion of robust IP protection for biopharma innovations before WTO and in current and future FTAs |